Humanity’s pursuit of delaying aging has endured since the dawn of civilization. In modern biomedical science, this pursuit has largely centered on stem cells.
If the human body is a sophisticated building, stem cells are versatile engineers: when organs age or sustain damage, stem cells can theoretically differentiate into any required cell type to repair time-related wear and tear. At the apex of the stem cell hierarchy are embryonic stem cells (ESCs).
First isolated from mice in 1981 by Martin Evans and Matthew Kaufman, and with human ESC lines successfully established in 1998 by James Thomson, these cells stunned the scientific world. They possess unlimited self-renewal capacity and can theoretically differentiate into all over 200 human cell types, appearing to remain perpetually young under the microscope, unlike somatic cells that readily undergo senescence.
However, this promising anti-aging approach faces critical barriers. Derived from the inner cell mass of blastocysts, ESC acquisition involves the destruction of early embryos, sparking intense ethical controversy. More alarmingly, their unrestricted pluripotency carries a high risk of teratoma formation when directly implanted in vivo.
This led to a groundbreaking hypothesis: what if we use only the "secretions" of ESCs, rather than the live cells themselves? What if the anti-aging code of ESCs is contained within the signaling molecules they release?
Recently, a team led by Professor Richard A. Cerione from Cornell University published a landmark study in the Journal of Biological Chemistry (JBC), a top biochemistry journal. The team not only confirmed the potent anti-senescence effects of extracellular vesicles (EVs) secreted by ESCs, but also deciphered the precise molecular mechanism underlying this process. This discovery may provide a way to harness the anti-aging power of ESCs while completely avoiding ethical risks and tumorigenic potential.
A Vital Message From the Origin of Life
To understand the study, we first clarify what extracellular vesicles (EVs) are.
For decades, scientists dismissed these tiny membrane vesicles secreted by cells as mere "garbage bags" for cellular waste disposal. However, recent research has overturned this view: EVs are in fact "information parcels" for intercellular communication, packed with proteins, lipids, and nucleic acids that deliver precise biological signals between cells.
The Cornell team found that pluripotent ESCs, while resisting senescence themselves, continuously release EVs (including microvesicles and exosomes) ranging from 70 to 500 nanometers in diameter into their surrounding environment.
To test the effects of these ESC-derived EVs, the researchers used extensively passaged mouse embryonic fibroblasts (MEFs), which displayed classic senescence features: slowed growth, enlarged and flattened morphology, and approximately 50% of cells staining positive for senescence-associated β-galactosidase (SA-β-gal), the gold-standard senescence marker.
When ESC-derived EVs were added to the culture medium of these senescent cells, a remarkable reversal occurred. The once stagnant, aging cells regained robust proliferative capacity, their morphology reverted to a compact, youthful state, and SA-β-gal positive cells plummeted to levels nearly matching young cells. Notably, the expression of SIRT1, a well-documented "longevity protein", was restored to high levels in these treated cells.
SIRT1, an NAD+-dependent deacetylase widely recognized as a master regulator of aging, typically declines sharply as cells senesce. ESC-derived EVs effectively reversed this age-related decline. This anti-senescence effect was not limited to fibroblasts; the team replicated the results in astrocytes, a critical brain cell type, showing consistent suppression of cellular senescence.
The Molecular Mechanism: The Secret Is on the Vesicle Surface
Previous research has focused on the microRNAs, enzymes, and other bioactive cargo carried inside EVs. However, the Cornell team’s findings revealed an unexpected mechanism: the key to the anti-aging effect lies on the surface of the EVs.
Biochemical analysis revealed that the surface of ESC-derived EVs is densely coated with fibronectin, an extracellular matrix protein. To verify its critical role, the team designed a definitive experiment: they gently treated the EVs with trypsin, an enzyme that digests only surface proteins without damaging the vesicles’ internal cargo. The result was striking: EVs stripped of surface fibronectin completely lost their anti-senescence capacity.
This demonstrated that ESC-derived EVs do not exert their effects by delivering internal cargo into cells, but rather via surface fibronectin binding to integrin, a receptor on the surface of senescent cells. This binding triggers a precise signaling cascade that reverses cellular senescence.
The Intracellular Signaling Cascade That Reverses Aging
The binding of fibronectin on EVs to integrin receptors initiates a sequential activation of intracellular signaling pathways:
- The binding rapidly activates Focal Adhesion Kinase (FAK) within the cell.
- Activated FAK then phosphorylates and activates AKT, a core kinase that regulates cell survival and proliferation.
- Activated AKT directly inhibits the activity of Glycogen Synthase Kinase 3 Beta (GSK3β) via phosphorylation at the Ser9 site.
- GSK3β is a negative regulator of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2), the master regulator of the cellular antioxidant response. In senescent cells, overactive GSK3β suppresses Nrf2, leading to the collapse of antioxidant defenses and accumulation of toxic reactive oxygen species (ROS), a primary driver of cellular aging.
- With GSK3β inhibited, Nrf2 accumulates in the cell, activating a battery of antioxidant genes to clear accumulated ROS, drastically reducing intracellular oxidative stress.
The end result is the reversal of cellular senescence: aging cells regain youthful function, healthy proliferation, and resistance to oxidative damage. The team confirmed the rigor of this pathway by individually inhibiting each component: blocking FAK or AKT completely eliminated the anti-senescence effect, while direct pharmacological inhibition of GSK3β replicated the EVs’ effects, restoring Nrf2 activity, reducing ROS, and rejuvenating senescent cells.
Notably, the team found that purified fibronectin alone, even at high concentrations, produced only minimal anti-senescence effects, far weaker than those of intact ESC-derived EVs. Artificially coating fibronectin onto EVs secreted by differentiated somatic cells also failed to replicate the potent effects of native ESC-derived EVs. This suggests that the specific spatial conformation of fibronectin on ESC-derived EVs, or potential synergistic effects from other components within the vesicles, are required for full anti-senescence activity — a natural delivery system that synthetic biology cannot yet fully replicate.
An Ethical, Non-Tumorigenic Anti-Aging Strategy
For decades, stem cell anti-aging has focused on regenerative medicine: replacing damaged or aged cells with stem cell-derived new cells. However, this Cornell study elevates our understanding to a new paradigm: preventive anti-aging.
Rather than replacing cells after they have senesced and died, ESC-derived EVs intervene early, delivering signals to cells under oxidative stress to clear toxic ROS, maintain youthful function, and prevent senescence before it takes hold.
This strategy offers critical advantages over direct stem cell transplantation:
- No live ESCs are used, eliminating the risk of teratoma formation.
- EVs have no nucleus and cannot undergo malignant proliferation, with a far superior safety profile.
- Once a stable ESC line is established (many existing lines have been used for decades), EVs can be continuously produced in bioreactors without repeated ethical concerns associated with embryo destruction.
Most excitingly, the GSK3β-Nrf2-ROS axis identified in this study is a highly promising drug target. This discovery opens new avenues for the treatment of aging-related diseases driven by oxidative stress, including neurodegenerative disorders (such as Alzheimer’s disease), cardiovascular disease, and even cancer prevention.
From the first isolation of mouse ESCs in 1981 to this 2025 breakthrough revealing the anti-aging power of ESC-derived EVs, we are moving closer to a future where we can rejuvenate aging cells not with organ transplants or live stem cells, but with these tiny, vital "information parcels" from the earliest stages of life, delivering a simple message to our tired cells: "Stay young."
References
[1] Evans, M., Kaufman, M. Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156 (1981). https://doi.org/10.1038/292154a0
[2] Enomoto, S., Hur, Y. H., Solodova, T., Neumann, J., Cerione, R. A., & Antonyak, M. A. (2025). Embryonic stem cell-derived extracellular vesicles delay cellular senescence by inhibiting oxidative stress. Journal of Biological Chemistry, 301(12), 110821. https://doi.org/10.1016/j.jbc.2025.110821